Biomarkers and Imaging Markers for ICH

Intracerebral hemorrhage (ICH) is one of the most serious subtypes of stroke, affecting approximately 2-3 million people worldwide each year. About one third of people with ICH die early after onset and the majority of survivors are left with major long-term disability. Today little is known about the characteristic changes in molecules from body samples and pictures from multimodality imaging scans. In this study, the investigators aim to reveal the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc, which will bring insights into pathophysiological mechanisms and addition of new tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.

Inclusion criteria

• Individuals aged 18-80 years
• Hematoma size is more than 5 ml
• Evidence of a spontaneous ICH on CT scan
• Patient within 72 hours of ictus
• Glasgow Coma Scale (GCS) Score of 5-15.
• The history of hypertension

Exclusion criteria

• Individuals with age < 18 years or > 80 years
• Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases.
• ICH secondary to tumor or trauma..
• If the haematological effects of any previous anticoagulants are not completely reversed.
• Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.